Full Year 2026 AFT Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- AFT Pharmaceuticals Ltd (ASX:AFP) achieved a 22% increase in revenue, reaching $254.7 million, bringing them closer to their $300 million revenue target.
- The company reported an operating profit of $24.4 million, slightly ahead of guidance, and a record EBITDA of $28.8 million.
- AFT Pharmaceuticals Ltd expanded its global footprint, with sales now in 87 countries and new market entries in Thailand and Taiwan.
- The company closed 9 licensing agreements during the financial year and is working on commercializing 7 R&D projects.
- AFT Pharmaceuticals Ltd increased its dividend, reflecting strong financial performance and confidence in future growth.
- Despite increased sales, profit growth has been relatively flat over the last four years due to significant investments in new business hubs.
- The international segment is still generating losses, primarily due to R&D expenses and the time required to scale new markets.
- The company faces challenges in the U.S. market, with the Combogesic Rapid launch delayed and no firm forecast available.
- There are ongoing regulatory delays in Europe, slowing down product rollouts from a recent acquisition.
- AFT Pharmaceuticals Ltd has increased its working capital and inventory levels to 5 months due to market uncertainties, impacting cash flow.
Thank you for standing by, and welcome to the AFT Pharmaceuticals FY26 full year results analyst briefing. (Operator Instructions) And finally, I would like to advise all participants that this call is being recorded.
I'd now like to welcome Hartley Atkinson, CEO, to begin the conference. Hartley, over to you.
Great. Thank you very much. So look, welcome, everyone. What we'll do is go through the investor presentation, and I will go through it and mention the page numbers just so we can keep track. So obviously, there is the disclaimer on page 2, so please be aware of the details in that notice.
And then clicking on to page 3. Yes, look, this is just quickly a summary of generally the business, what we're doing. So just reaffirming our $300 million revenue target. We sort of can see good growth this last year, and that target is well and truly now in sight. So we managed to get to $254.7 million, up 22%, which is about a 17.6
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
